- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Lupin Limited — Updates, 04-06-2026: Press Release
04-06-2026 | 10:59 pm
04-06-2026 | 10:59 pm
Lupin secured U.S. FDA approval for Ranluspec™ (ranibizumab), an interchangeable biosimilar to Lucentis®. This significantly expands Lupin's biosimilars portfolio, enhancing access to critical vision therapies. It's the only approved interchangeable biosimilar ranibizumab in the U.S. in both vials and pre-filled syringes.
No comments yet. Be the first to comment!